REGNRegeneron Pharmaceuticals, Inc.

Ticker: REGN | Price: $912.66 | Today's Change: +11.47% Filing: 10-Q | Filed with the SEC on: October 30, 2026

---

What Happened

Regeneron Pharmaceuticals filed its 10-Q quarterly report with the SEC on October 30, 2026, disclosing results for the third quarter of fiscal year 2026. The company reported revenues of $10.46 billion (as measured by revenue from contracts with customers excluding assessed tax) for Q3 FY2026, alongside operating income of $2.698 billion and net income of $808.7 million. Diluted earnings per share came in at $33.61, with basic EPS of $34.83, underscoring the scale of the company's profitability in the period.

---

Why It Matters

The Q3 FY2026 top-line figure of $10.46 billion represents a striking revenue base for a single quarter and signals that Regeneron's commercial portfolio — anchored by its key therapies — continues to generate substantial and growing cash flows. Operating income of $2.698 billion points to strong operational leverage, meaning the company is converting a meaningful share of its revenue into profit. For investors, the immediate read is clear: the market's +11.47% single-day reaction reflects significant positive surprise relative to expectations. Net income of $808.7 million and diluted EPS of $33.61 confirm that profitability at the bottom line, while lower than operating income suggests (indicating notable below-the-line costs or tax effects), remains robust in absolute terms.

---

Analysis

Several elements of this filing are worth watching closely:

• Revenue scale: A single-quarter revenue figure of $10.46 billion places Regeneron firmly among the largest revenue generators in the biopharmaceutical sector for this period. This level of revenue implies continued strong demand across the portfolio, though a breakdown by product line is not available in the structured data provided here.

• EPS vs. net income gap: Diluted EPS of $33.61 on net income of $808.7 million implies an approximate diluted share count in the range of ~24 million shares — a figure that reflects Regeneron's historically disciplined share count management. Investors should review the full filing for any share repurchase activity or dilution events during the quarter.

• Operating-to-net income spread: Operating income of $2.698 billion compared to net income of $808.7 million is a gap of nearly $1.9 billion, which warrants scrutiny. This differential likely reflects interest expenses, tax provisions, or other non-operating charges of material size — details that will be found in the full income statement and notes within the 10-Q.

• Stock reaction: A move of +11.47% on the day of a quarterly earnings release of this magnitude is consistent with results that materially exceeded the market's prior expectations. The sustainability of the share price at these levels will depend on forward guidance, pipeline readouts, and competitive dynamics, none of which are captured in the structured XBRL data provided.

The filing as a whole depicts a company at a significant commercial inflection point, and investors should read the complete 10-Q — including management's discussion and analysis — for full context on drivers, risks, and outlook.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Regeneron Pharmaceuticals' 10-Q filing submitted to the SEC on October 30, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation of any kind. No rating or price target is issued or implied. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Source

Filed with the SEC on 2026-10-30. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/regn-20260930.htm